# US 2026/0062403 A1 · Kinase inhibitors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0062403 A1
- Document ID: US20260062403A1
- Status: Published application
- Kind: A1
- Application number: 19/300,497
- Filed: 2025-08-14
- Published: 2026-03-05
- Earliest claimed: 2019-02-22
- Assignees: Insilico Medicine IP Limited
- Applicants: Insilico Medicine IP Limited
- Inventors: Aleksandr Aliper; Vladimir Aladinskiy; Aleksandrs Zavoronkovs
- Web page: https://patentgrep.com/patent/US20260062403A1

## CPC

- C07D 405/04: directly linked by a ring-member-to-ring-member bond
- A61K 31/4164: 1,3-Diazoles
- A61K 31/4439: containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole (nicotine A61K31/465)
- A61K 31/506: not condensed and containing further heterocyclic rings
- C07D 401/04: directly linked by a ring-member-to-ring-member bond
- C07D 401/14: containing three or more hetero rings
- C07D 403/04: directly linked by a ring-member-to-ring-member bond
- C07D 403/14: containing three or more hetero rings
- C07D 405/14: containing three or more hetero rings
- C07D 409/04: directly linked by a ring-member-to-ring-member bond
- C07D 413/04: directly linked by a ring-member-to-ring-member bond
- C07D 417/04: directly linked by a ring-member-to-ring-member bond
- C07D 471/04: Ortho-condensed systems
- C07D 491/048: the oxygen-containing ring being five-membered
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

A TNIK and/or MAP4K4 kinase inhibitor can include: Formula A, derivative, prodrug, salt, stereoisomer, tautomer polymorph, or solvate thereof, or having chirality at any chiral center, wherein: ring 1 is an aromatic ring with or without hetero atoms; ring 2 is a hetero aromatic ring; ring 3 includes at least one hetero aromatic ring and optionally at least one cycloaliphatic ring fused with the at least one hetero aromatic ring; ring 4 is an aromatic ring with or without hetero atoms; Y is a bond or a linker; Y1 is a linker; each n is independently 0, 1, or 2; each o is independently 0, 1, 2, 3, 4, or 5; each R1, R6, R11, and R12 is independently a substituent; and RA is a ring structure, straight aliphatics, or branched aliphatics, which can be substituted or unsubstituted, any with or without hetero atoms.

## Claims

### Claim 1

A compound, comprising:
a structure of Formula A, a salt thereof, or a stereoisomer thereof,
wherein:
ring 1 is an aromatic ring with or without hetero atoms;
ring 2 is a hetero aromatic ring;
ring 3 includes at least one hetero aromatic ring and optionally at least one cycloaliphatic ring fused with the at least one hetero aromatic ring;
ring 4 is an aromatic ring with or without hetero atoms;
Y is a bond or a linker;
Y1 is a ketone, hydrazide, carbohydrazide, hydroxy-substituted amide, alkyl-substituted amide, carboximidamide, or sulfonimidamide;
each n is independently 0, 1, or 2;
each o is independently 0, 1, 2, 3, 4, or 5;
each R1, R6, R11, and R12 is independently a chemical moiety; and
wherein the compound includes at least one of the following provisions:
when Y is a bond, RA is a hydrogen, aromatic ring, cycloaliphatic ring, straight aliphatic chain, or branched aliphatic chain, any of which can be substituted or unsubstituted, or with or without hetero atoms, or combinations thereof, or
when Y is a chemical moiety, RA is an aromatic ring, cycloaliphatic ring, straight aliphatic chain, or branched aliphatic chain, which can be substituted or unsubstituted, or with or without hetero atoms, or combinations thereof, or
the compound includes at least one of the following:
when ring 1 is a phenyl group, at least one of: ring 2 is not a furanyl group; ring 3 is not an imidazolyl group; or ring 4 is not phenyl group;
when ring 2 is a furanyl group, at least one of: ring 1 is not a phenyl group; ring 3 is not an imidazolyl group, or ring 4 is not a phenyl group;
when ring 3 is an imidazolyl group, at least one of: ring 1 is not a phenyl group; ring 2 is not a furanyl group; or ring 4 is not a phenyl group; or
when ring 4 is a phenyl group, at least one of: ring 1 is not a phenyl group; ring 2 is not a furanyl group; or ring 3 is not an imidazolyl group.

### Claim 2

(canceled)

### Claim 3 (depends on 1)

The compound of claim 1, wherein the compound includes:
ring 1 is a phenyl group, pyridyl group, or pyrimidinyl group;
ring 2 is a 5-membered or 6 membered hetero aromatic ring;
ring 3 includes a 5-membered hetero aromatic ring or a 5-membered hetero aromatic ring fused with a 6-membered hetero aromatic ring that is fused with a 5-membered cycloaliphatic ring, where the bond to Y is through the 5-membered hetero aromatic ring;
ring 4 is a phenyl group, pyridyl group, pyrimidyl group, or triazinyl group;
Y is a bond or an aliphatic linker; and
wherein when Y is a bond RA is not a 5-membered cycloaliphatic ring.

### Claim 4 (depends on 1)

The compound of claim 1, wherein:
ring 1 is a phenyl group, pyridyl group, or pyrimidinyl group, when ring 1 is pyridyl or Pyrimidinyl the nitrogens are located at the para, meta, or ortho position in the ring;
ring 2 is a furanyl group, thiophenyl group, pyrrolyl group, oxazolyl group, thiazolyl group; imidazolyl group, triazolyl group, or pyridyl group;
ring 3 is a imidazolyl group, triazolyl group, or cyclopenta-pyrrolo-pyridinyl fused ring group; or cyclopenta-furo-pyridinyl group;
ring 4 is a phenyl group, pyridyl group, pyrimidyl group, or triazinyl group, when ring 4 is pyridyl the nitrogen is located at the para, meta, or ortho positions in the ring; when ring 4 is pyrimidyl group, the nitrogens are at the meta or ortho positions in the ring; and
Y is a bond or C1-C6 aliphatic.

### Claim 5 (depends on 1)

The compound of claim 1, wherein:
when Y is a C1-C6 aliphatic linker, RA is a C3-C6 cycloaliphatic ring, C5-C6 hetero cycloaliphatic ring, aromatic ring, C1-C12 straight aliphatic, or C1-C12 branched aliphatic, which can be substituted or unsubstituted, any with or without hetero atoms, or
when Y is a bond, RA is a not a C6-C6 cycloaliphatic ring.

### Claim 6 (depends on 1)

The compound of claim 1, wherein each R1, R6, R11, and R12 is independently hydrogen, F, Br, Cl, I, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, isopropyl, tert-butyl, trifluoromethyl, oxygen, oxide, hydroxy, methoxy, ethoxy, propoxy, butoxy, pentoxy, hexoxy, heptoxy, octoxy, trifluromethyloxy, methylthio, ethylthio, propylthio, butylthio, pentylthio, hexylthio, heptylthio, octylthio, methylalcohol, ethylalcohol, propylalcohol, butylalcohol, pentylalcohol, hexylalcohol, heptylalcohol, octylalcohol, acetyl, carboxylic acid, alkyl carboxylic acid, methyl carboxylic acid, ethyl carboxylic acid, propionyl, butyryl, acetamide, methylacetamide, ethylacetamide, propionamide, butyramide, pentanamide, hexanamide, heptanamide, octanamide, fluoromethyl, bifluoromethyl, trifluoromethyl, fluoromethoxy, bifluoromethoxy, trifluoromethoxy, methyl ester, ethyl ester, propyl ester, butyl ester, pentyl ester, hexyl ester, heptyl ester, octyl ester, methylsulfanyl, thiomethyl, ethylsulfanyl, propylsulfanyl, butylsulfanyl, pentylsulfanyl, hexylsulfanyl, heptylsulfanyl, octylsulfanyl, sulfamoyl, methylpiperazinyl, piperazinyl, hydroxyethylpiperazinyl, bis(2-hydroxyethyl)amino, morpholino, or combinations thereof.

### Claim 7 (depends on 1)

The compound of claim 1, wherein R11 and R12 are hydrogen or nothing, and each R1 or R6 is independently hydrogen, F, Br, Cl, I, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, isopropyl, tert-butyl, trifluoromethyl, oxygen, oxide, hydroxy, methoxy, ethoxy, propoxy, butoxy, pentoxy, hexoxy, heptoxy, octoxy, trifluromethyloxy, methylthio, ethylthio, propylthio, butylthio, pentylthio, hexylthio, heptylthio, octylthio, methylalcohol, ethylalcohol, propylalcohol, butylalcohol, pentylalcohol, hexylalcohol, heptylalcohol, octylalcohol, acetyl, carboxylic acid, alkyl carboxylic acid, methyl carboxylic acid, ethyl carboxylic acid, propionyl, butyryl, acetamide, methylacetamide, ethylacetamide, propionamide, butyramide, pentanamide, hexanamide, heptanamide, octanamide, fluoromethyl, bifluoromethyl, trifluoromethyl, fluoromethoxy, bifluoromethoxy, trifluoromethoxy, methyl ester, ethyl ester, propyl ester, butyl ester, pentyl ester, hexyl ester, heptyl ester, octyl ester, methylsulfanyl, thiomethyl, ethylsulfanyl, propylsulfanyl, butylsulfanyl, pentylsulfanyl, hexylsulfanyl, heptylsulfanyl, octylsulfanyl, sulfamoyl, methylpiperazinyl, piperazinyl, hydroxyethylpiperazinyl, bis(2-hydroxyethyl)amino, morpholino, or combinations thereof.

### Claim 8 (depends on 7)

The compound of claim 7, wherein each R1 is independently hydrogen, F, Br, Cl, I, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, isopropyl, tert-butyl, trifluoromethyl, hydroxy, methoxy, ethoxy, propoxy, butoxy, pentoxy, hexoxy, heptoxy, octoxy, trifluromethyloxy, or combinations thereof.

### Claim 9 (depends on 1)

The compound of claim 1, wherein R11 and R12 are hydrogen or nothing, and each R6 is independently hydrogen, F, Br, Cl, I, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, isopropyl, tert-butyl, trifluoromethyl, oxygen, oxide, hydroxy, methoxy, ethoxy, propoxy, butoxy, pentoxy, hexoxy, heptoxy, octoxy, trifluromethyloxy, methylthio, ethylthio, propylthio, butylthio, pentylthio, hexylthio, heptylthio, octylthio, methylalcohol, ethylalcohol, propylalcohol, butylalcohol, pentylalcohol, hexylalcohol, heptylalcohol, octylalcohol, acetyl, carboxylic acid, alkyl carboxylic acid, methyl carboxylic acid, ethyl carboxylic acid, propionyl, butyryl, acetamide, methylacetamide, ethylacetamide, propionamide, butyramide, pentanamide, hexanamide, heptanamide, octanamide, fluoromethyl, bifluoromethyl, trifluoromethyl, fluoromethoxy, bifluoromethoxy, trifluoromethoxy, methyl ester, ethyl ester, propyl ester, butyl ester, pentyl ester, hexyl ester, heptyl ester, octyl ester, methylsulfanyl, thiomethyl, ethylsulfanyl, propylsulfanyl, butylsulfanyl, pentylsulfanyl, hexylsulfanyl, heptylsulfanyl, octylsulfanyl, sulfamoyl, methylpiperazinyl, piperazinyl, hydroxyethylpiperazinyl, bis(2-hydroxyethyl)amino, morpholino, or combinations thereof.

### Claim 10

(canceled)

### Claim 11 (depends on 1)

The compound of claim 1, wherein RA is from hydrogen, cyclopentyl, tetrahydrofuranyl, pyrrolidinyl, piperidinyl, pyridinyl, pyrimidinyl, bicycloheptanyl, bicyclooctanyl, bicyclo[3.1.1]heptan-3yl, bicyclo[2.2.2octan-2yl, bicyclo[3.2.1]octan-3-yl, fluorotetrahydrofuranyl, difluorotetrahydrofuranyl, oxetanyl, hydroxycyclopentyl, methylcyclopentyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, isopropyl, tert-butyl, hydroxypropanyl, trifluoromethyl, methoxy, ethoxy, propoxy, butoxy, pentoxy, hexoxy, heptoxy, octoxy, phenyl, or combinations thereof.

### Claim 12

A compound of a structure of Formula A1 a salt thereof, or a stereoisomer thereof,
wherein:
ring D is a ring structure having one or more rings fused together;
each R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, and R12 is independently a chemical moiety;
the X3, X7, X8, X9, X10, X11, X12, X13, X14 and X20 are each independently a carbon or a hetero atom with or without a substituent;
Y1 is a linker;
m is 1, 2, or 3; and
n is 0, 1, or 2;
wherein when an X group is N in an aromatic ring, the R group bonded thereto is nothing;
when the dashed line forms a double bond X12 is N.

### Claim at position 13

13-28. (canceled)

### Claim 29

A compound of a structure of Formula A2, a salt thereof, or a stereoisomer thereof,
wherein:
each R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, and R12 is independently a chemical moiety;
the X1, X2, X3, X6, X7, X8, X9, X10, X11, X12, and X20 are each independently a carbon or a hetero atom with or without a substituent;
Y is a bond or a linker;
Y1 is a ketone, hydrazide, carbohydrazide, hydroxy-substituted amide, alkyl-substituted amide, carboximidamide, or sulfonimidamide;
m is 1, 2, or 3; and
n is 0, 1, or 2;
when Y is a bond, RA is hydrogen, aromatic cycloaliphatic, straight aliphatic, or branched aliphatic, any substituted or unsubstituted, any with or without hetero atoms;
when Y is a linker, RA is an aromatic, cycloaliphatic, straight aliphatic, or branched aliphatic, any substituted or unsubstituted, any with or without hetero atoms;
wherein when an X group is N in an aromatic ring, the R group bonded thereto is nothing;
when the dashed line forms a double bond X12 is N.

### Claim 30 (depends on 1)

A pharmaceutical composition comprising the compound of claim 1, a salt thereof, or a stereoisomer thereof, and a pharmaceutically acceptable carrier.

### Claim 31 (depends on 1)

A method of inhibiting a TNIK kinase comprising contacting the TNIK kinase with the compound of claim 1, a salt thereof, or a stereoisomer thereof.

### Claim 32 (depends on 1)

A method of treating a disease or condition in a subject in need thereof, comprising administering the compound of claim 1, a salt thereof, or a stereoisomer thereof to the subject.

### Claim 33 (depends on 12)

A pharmaceutical composition comprising the compound of claim 12, a salt thereof, or a stereoisomer thereof, and a pharmaceutically acceptable carrier.

### Claim 34 (depends on 12)

A method of inhibiting a TNIK kinase comprising contacting the TNIK kinase with the compound of claim 12, a salt thereof, or a stereoisomer thereof.

### Claim 35 (depends on 12)

A method of treating a disease or condition in a subject in need thereof, comprising administering the compound of claim 12, a salt thereof, or a stereoisomer thereof to the subject.

### Claim 36 (depends on 29)

A pharmaceutical composition comprising the compound of claim 29, a salt thereof, or a stereoisomer thereof, and a pharmaceutically acceptable carrier.

### Claim 37 (depends on 29)

A method of inhibiting a TNIK kinase comprising contacting the TNIK kinase with the compound of claim 29, a salt thereof, or a stereoisomer thereof.

### Claim 38 (depends on 29)

A method of treating a disease or condition in a subject in need thereof, comprising administering the compound of claim 29, a salt thereof, or a stereoisomer thereof to the subject.
